NO994181D0 - S-2'-(2-(1-metyl-2-piperidyl)etyl)cinnamanilid som 5-HT2 reseptor antagonist - Google Patents

S-2'-(2-(1-metyl-2-piperidyl)etyl)cinnamanilid som 5-HT2 reseptor antagonist

Info

Publication number
NO994181D0
NO994181D0 NO994181A NO994181A NO994181D0 NO 994181 D0 NO994181 D0 NO 994181D0 NO 994181 A NO994181 A NO 994181A NO 994181 A NO994181 A NO 994181A NO 994181 D0 NO994181 D0 NO 994181D0
Authority
NO
Norway
Prior art keywords
mpec
cinnamanilide
piperidyl
ethyl
methyl
Prior art date
Application number
NO994181A
Other languages
English (en)
Other versions
NO318443B1 (no
NO994181L (no
Inventor
Moh Samir Amer
Original Assignee
Moh Samir Amer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25204013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO994181(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Moh Samir Amer filed Critical Moh Samir Amer
Publication of NO994181D0 publication Critical patent/NO994181D0/no
Publication of NO994181L publication Critical patent/NO994181L/no
Publication of NO318443B1 publication Critical patent/NO318443B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19994181A 1997-02-28 1999-08-27 S-2'-(2-(1-metyl-2-piperidyl)etyl)cinnamanilid som 5-HT2 reseptor-antagonist NO318443B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/810,503 US5780487A (en) 1995-08-07 1997-02-28 S-2'- 2-(1-methyl-2-piperidyl) ethyl! cinnamanilide
PCT/US1998/001304 WO1998038165A1 (en) 1997-02-28 1998-01-23 S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide as a 5-ht2 receptor antagonist

Publications (3)

Publication Number Publication Date
NO994181D0 true NO994181D0 (no) 1999-08-27
NO994181L NO994181L (no) 1999-10-27
NO318443B1 NO318443B1 (no) 2005-03-21

Family

ID=25204013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19994181A NO318443B1 (no) 1997-02-28 1999-08-27 S-2'-(2-(1-metyl-2-piperidyl)etyl)cinnamanilid som 5-HT2 reseptor-antagonist

Country Status (11)

Country Link
US (1) US5780487A (no)
EP (1) EP0973741B1 (no)
JP (1) JP3492378B2 (no)
KR (1) KR20000075696A (no)
AT (1) ATE242765T1 (no)
AU (1) AU750603B2 (no)
CA (1) CA2282840C (no)
DE (1) DE69815518T2 (no)
ES (1) ES2201440T3 (no)
NO (1) NO318443B1 (no)
WO (1) WO1998038165A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10036802A1 (de) * 2000-07-28 2002-02-07 Tesa Ag Haftklebemassen auf Basis von Blockcopolymeren der Struktur P(A)-P(B)-P(A)
JP2005518371A (ja) * 2001-12-10 2005-06-23 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療に於けるこれらの使用
US7600626B2 (en) * 2002-06-13 2009-10-13 Cummins-Allison Corp. Currency processing and strapping systems and methods
DE10358525A1 (de) 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
CA2629351A1 (en) * 2005-11-17 2007-10-04 Novartis Ag Organic compounds
BRPI0618790A2 (pt) * 2005-11-17 2011-09-13 Novartis Ag compostos orgánicos
CN102186482A (zh) * 2008-10-22 2011-09-14 萨姆阿穆尔公司 治疗肺动脉高血压的方法
WO2012026914A1 (en) * 2010-08-23 2012-03-01 Sam Amer & Co., Inc. Methods and compositions for treating internal and external hemorrhoids
WO2013070236A1 (en) * 2011-11-11 2013-05-16 Ventrus Biosciences, Inc. Methods and compositions for treating hemorrhoids while providing local anesthetic and anti-inflammatory effects
CN102924374B (zh) * 2012-02-15 2014-04-16 湖北欣瑞康医药科技有限公司 喹啉-4-羧酸衍生物的制备方法
CH706161A1 (de) 2012-03-15 2013-10-15 Oti Greentech Group Ag Ölrückgewinnung.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064254A (en) * 1971-03-03 1977-12-20 Mead Johnson & Company Substituted piperidines therapeutic process and compositions
US4000143A (en) * 1971-03-03 1976-12-28 Mead Johnson & Company Substituted piperidines
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
GB9402688D0 (en) * 1994-02-11 1994-04-06 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
JP3492378B2 (ja) 2004-02-03
KR20000075696A (ko) 2000-12-26
EP0973741A1 (en) 2000-01-26
DE69815518D1 (en) 2003-07-17
EP0973741B1 (en) 2003-06-11
JP2001527521A (ja) 2001-12-25
ATE242765T1 (de) 2003-06-15
AU750603B2 (en) 2002-07-25
AU6037798A (en) 1998-09-18
US5780487A (en) 1998-07-14
NO318443B1 (no) 2005-03-21
CA2282840C (en) 2006-04-11
WO1998038165A1 (en) 1998-09-03
NO994181L (no) 1999-10-27
ES2201440T3 (es) 2004-03-16
CA2282840A1 (en) 1998-09-03
DE69815518T2 (de) 2004-04-22

Similar Documents

Publication Publication Date Title
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
NO994181L (no) S-2'-(2-(1-metyl-2-piperidyl)etyl)cinnamanilid som 5-HT2 reseptor-antagonist
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
KR950017957A (ko) 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
BR0315143A (pt) Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto
ES2089665T3 (es) Terazosina polimorfa y composicion farmaceutica.
GT199700037A (es) Composiciones farmaceuticas para el tratamiento de la rinitis
IL111127A (en) Short-acting calcium antagonist dihydropyridines process for their preparation and pharmaceutical compositions containing them
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
ES2102994T3 (es) Derivados de benzisotiazolinona-1-dioxido como inhibidores de elastasa.
IT1250049B (it) Composti triciclici.
RU94046107A (ru) Замещенные производные 2 бета - морфолинандростана, способ их получения, фармакомпозиция, содержащая их
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
EA200001061A1 (ru) Фармацевтическая композиция
MY111055A (en) Pharmaceutical composition and process for the preparation thereof
GEP20012389B (en) Benzoxazinone Dopamine D4 Receptor Antagonists, Pharmaceutical Composition Containing the Same and Method for Treatment of Psychosis or Schizophrenia
AU3623399A (en) Use of benzofuroxan derivatives in treating angina pectoris
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
HRP20060040A2 (en) PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS, AS WELL AS PROCESS FOR THE SYNTHESIS OF THE MIXTURE OF ISOMERS AND THE PURE ISOMERS
AR008245A1 (es) Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados
ECSP941088A (es) Composiciones
DK0556813T3 (da) Amfotere tricykliske forbindelser som antihistaminske og antiallergiske midler
FI950209A0 (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
KR890701584A (ko) 20, 21-디노르에비나메닌의 신규 치환 유도체, 그의 제조 방법 및 이 방법으로 얻는 신규 중간체, 약제로서의 그의 용도 및 그를 함유하는 제약 조성물